Millipore Sigma Vibrant Logo

559398 InSolution™ SB 203580 - Calbiochem

InSolution SB 203580, CAS 152121-47-6, is a 1 mg/ml solution of SB 203580 in DMSO. A cell-permeable, selective, reversible inhibitor of p38 MAP kinase (IC₅₀ = 34 nM in vitro, 600 nM in cells).

InSolution™ SB 203580 - Calbiochem MSDS (material safety data sheet) or SDS, CoA and CoQ, dossiers, brochures and other available documents.

Synonyms: InSolution™ p38 MAP Kinase Inhibitor XVI

Primary Target: P38MAPK
View Products on Sigmaaldrich.com
559398
View Pricing & Availability

Overview

Replacement Information

Key Spec Table

Empirical Formula
C₂₁H₁₆FN₃OS

Pricing & Availability

Catalogue Number AvailabilityPackaging Qty/Pack Price Quantity
559398-1ML
Retrieving availability...
—
Limited Availability Limited Availability
In Stock 
Discontinued
Limited Quantities Available
Availability to be confirmed
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      Contact Customer Service

      		 Plastic ampoule 1 ml
      Retrieving price...
      Price could not be retrieved
      Minimum Quantity is a multiple of
      Maximum Quantity is
      Upon Order Completion More Information
      You Saved ()
       
      —
      Request Pricing
      		 —
      Description
      Catalogue Number559398
      Brand Family Calbiochem®
      SynonymsInSolution™ p38 MAP Kinase Inhibitor XVI
      References
      ReferencesPowell, D.J., et al. 2003. Mol. Cell Biol. 23, 7794.
      Davies, S.P., et al. 2000. Biochem. J. 351, 95.
      Iwasaki, S., et al. 1999. J. Biol. Chem. 274, 26503.
      Gallagher, T.F., et al. 1997. Bioorg. Med. Chem. 5, 49.
      LoGrasso, P.V., et al. 1997. Biochem. 36, 10422.
      Hazzalin, C.A., et al. 1996. Curr. Biol. 6, 1028.
      Kramer, R.M., et al. 1996. J. Biol. Chem. 271, 27723.
      Saklatvala, J., et al. 1996. J. Biol. Chem. 271, 6586.
      Cuenda, A., et al. 1995. FEBS Lett. 364, 229.
      Gallagher, T.F., et al. 1995. Bioorg. Med. Chem. Lett. 5, 1171.
      Lee, J.C., et al. 1994. Nature 372, 739.
      Product Information
      ATP CompetitiveY
      FormLiquid
      FormulationA 1 mg/ml solution of SB 203580 (Cat. No. 559389) in anhydrous DMSO.
      Hill FormulaC₂₁H₁₆FN₃OS
      Chemical formulaC₂₁H₁₆FN₃OS
      ReversibleY
      Structure formula ImageStructure formula Image
      Quality LevelMQ100
      Applications
      ApplicationInSolution SB 203580, CAS 152121-47-6, is a 1 mg/ml solution of SB 203580 in DMSO. A cell-permeable, selective, reversible inhibitor of p38 MAP kinase (IC₅₀ = 34 nM in vitro, 600 nM in cells).
      Biological Information
      Primary TargetP38MAPK
      Primary Target IC<sub>50</sub>34 nM in vitro, 600 nM in cells against p38 MAPK; 50-100 nM Inhibiting IL-1 and TNF-α production from LPS-stimulated human monocytes and the human monocyte cell line THP-1; 0.2-1.0 µM inhibiting platelet aggregation by collagen
      Purity≥98% by HPLC
      Physicochemical Information
      Cell permeableY
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      R PhraseR: 36/38

      Irritating to eyes and skin.
      S PhraseS: 24/25-26

      Avoid contact with skin and eyes.
      In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Blue Ice Only
      Toxicity Irritant
      Storage -20°C
      Protect from Light Protect from light
      Do not freeze Ok to freeze
      Special InstructionsFollowing initial thaw, aliquot, purge with inert gas, and freeze (-20°C).
      Packaging Information
      Packaged under inert gas Packaged under inert gas
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Catalogue Number GTIN
      559398-1ML 04055977192636

      Documentation

      InSolution™ SB 203580 - Calbiochem MSDS

      Title

      Safety Data Sheet (SDS) 

      InSolution™ SB 203580 - Calbiochem Certificates of Analysis

      TitleLot Number
      559398

      References

      Reference overview
      Powell, D.J., et al. 2003. Mol. Cell Biol. 23, 7794.
      Davies, S.P., et al. 2000. Biochem. J. 351, 95.
      Iwasaki, S., et al. 1999. J. Biol. Chem. 274, 26503.
      Gallagher, T.F., et al. 1997. Bioorg. Med. Chem. 5, 49.
      LoGrasso, P.V., et al. 1997. Biochem. 36, 10422.
      Hazzalin, C.A., et al. 1996. Curr. Biol. 6, 1028.
      Kramer, R.M., et al. 1996. J. Biol. Chem. 271, 27723.
      Saklatvala, J., et al. 1996. J. Biol. Chem. 271, 6586.
      Cuenda, A., et al. 1995. FEBS Lett. 364, 229.
      Gallagher, T.F., et al. 1995. Bioorg. Med. Chem. Lett. 5, 1171.
      Lee, J.C., et al. 1994. Nature 372, 739.

      Citations

      Title
    • Alexandra Thiel, et al. (2006) Expression of Cyclooxygenase-2 Is Regulated by Glycogen Synthase Kinase-3beta in Gastric Cancer Cells. Journal of Biological Chemistry 281, 4564-4569.
    • Bysani Chandrasekar, et al. (2005) The pro-atherogenic cytokine interleukin-18 induces CXCL16 expression in rat aortic smooth muscle cells via MyD88, interleukin-1 receptor-associated kinase, tumor necrosis factor receptor-associated factor 6, c-Src, phosphatidylinositol 3-kinase, Akt, c-J. Journal of Biological Chemistry 280, 26263-26277.
    • Guadalupe Sabio, et al. (2005) p38γ regulates the localisation of SAP97 in the cytoskeleton by modulating its interaction with GKAP. The EMBO Journal 24, 1134-1145.
    • Jose G. Trevino, et al. (2005) Expression and activity of Src regulate interleukin-8 expression in pancreatic adenocarcinoma cells: implications for angiogenesis. Cancer Research 65, 7214-7222.
    • Wojciech Wojciechowski, et al. (2005) Enhanced Expression of CD20 in Human Tumor B Cells is Controlled Through ERK-Dependent Mechanisms. Journal of Immunology 174, 7859-7868.
    • Yung-Luen Yu, et al. (2005) MAP kinase-mediated phosphorylation of GATA-1 promotes Bcl-XL expression and cell survival. Journal of Biological Chemistry 280, 29533-29542.
    • Naoto Inukai, et al. (2004) A novel hydrogen peroxide-induced phosphorylation and ubiquitination pathway leading to RNA polymerase II proteolysis. Journal of Biological Chemistry 279, 8190-8195.
      		•
      Data Sheet

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision05-October-2007 RFH
      SynonymsInSolution™ p38 MAP Kinase Inhibitor XVI
      DescriptionA highly specific, cell-permeable inhibitor of p38 kinase (IC50 = 34 nM in vitro, 600 nM in cells). Also known as reactivating kinase (RK) and CSBP (cytokine synthesis anti-inflammatory drug binding protein). Does not significantly inhibit JNK or p42 MAP kinase even at 100 µM. Inhibits IL-1 and TNF-α production from LPS-stimulated human monocytes and the human monocyte cell line THP-1 (IC50 = 50-100 nM). SB 203580 has also been shown to be an effective inhibitor of inflammatory cytokine production in vivo in both mice and rats.
      FormLiquid
      FormulationA 1 mg/ml solution of SB 203580 (Cat. No. 559389) in anhydrous DMSO.
      Intert gas (Yes/No) Packaged under inert gas
      Chemical formulaC₂₁H₁₆FN₃OS
      Structure formulaStructure formula
      Purity≥98% by HPLC
      Storage Protect from light
      -20°C
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing initial thaw, aliquot, purge with inert gas, and freeze (-20°C).
      Toxicity Irritant
      ReferencesPowell, D.J., et al. 2003. Mol. Cell Biol. 23, 7794.
      Davies, S.P., et al. 2000. Biochem. J. 351, 95.
      Iwasaki, S., et al. 1999. J. Biol. Chem. 274, 26503.
      Gallagher, T.F., et al. 1997. Bioorg. Med. Chem. 5, 49.
      LoGrasso, P.V., et al. 1997. Biochem. 36, 10422.
      Hazzalin, C.A., et al. 1996. Curr. Biol. 6, 1028.
      Kramer, R.M., et al. 1996. J. Biol. Chem. 271, 27723.
      Saklatvala, J., et al. 1996. J. Biol. Chem. 271, 6586.
      Cuenda, A., et al. 1995. FEBS Lett. 364, 229.
      Gallagher, T.F., et al. 1995. Bioorg. Med. Chem. Lett. 5, 1171.
      Lee, J.C., et al. 1994. Nature 372, 739.
      Citation
    • Alexandra Thiel, et al. (2006) Expression of Cyclooxygenase-2 Is Regulated by Glycogen Synthase Kinase-3beta in Gastric Cancer Cells. Journal of Biological Chemistry 281, 4564-4569.
    • Bysani Chandrasekar, et al. (2005) The pro-atherogenic cytokine interleukin-18 induces CXCL16 expression in rat aortic smooth muscle cells via MyD88, interleukin-1 receptor-associated kinase, tumor necrosis factor receptor-associated factor 6, c-Src, phosphatidylinositol 3-kinase, Akt, c-J. Journal of Biological Chemistry 280, 26263-26277.
    • Guadalupe Sabio, et al. (2005) p38γ regulates the localisation of SAP97 in the cytoskeleton by modulating its interaction with GKAP. The EMBO Journal 24, 1134-1145.
    • Jose G. Trevino, et al. (2005) Expression and activity of Src regulate interleukin-8 expression in pancreatic adenocarcinoma cells: implications for angiogenesis. Cancer Research 65, 7214-7222.
    • Wojciech Wojciechowski, et al. (2005) Enhanced Expression of CD20 in Human Tumor B Cells is Controlled Through ERK-Dependent Mechanisms. Journal of Immunology 174, 7859-7868.
    • Yung-Luen Yu, et al. (2005) MAP kinase-mediated phosphorylation of GATA-1 promotes Bcl-XL expression and cell survival. Journal of Biological Chemistry 280, 29533-29542.
    • Naoto Inukai, et al. (2004) A novel hydrogen peroxide-induced phosphorylation and ubiquitination pathway leading to RNA polymerase II proteolysis. Journal of Biological Chemistry 279, 8190-8195.
      		•